首页> Cytokine & growth factor reviews> COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.

COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.

导出 OA

翻译打印收藏纠错

第一作者： H C,Hasselbalch

第一单位： Department of Hematology, Zealand University Hospital, Roskilde, Denmark. Electronic address: hans.hasselbalch@gmail.com.

作者： H C,Hasselbalch ^[1] ; V,Skov ^[2] ; L,Kjær ^[2] ; C,Ellervik ^[3] ; A,Poulsen ^[4] ; T D,Poulsen ^[4] ; C H,Nielsen ^[5]

作者单位： Department of Hematology, Zealand University Hospital, Roskilde, Denmark. Electronic address: hans.hasselbalch@gmail.com. ^[1] Department of Hematology, Zealand University Hospital, Roskilde, Denmark. ^[2] Department of Research, Production, Innovation, Region Zealand, Denmark; Department of Pathology, Harvard Medical School, Boston, MA, United States; Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, United States. ^[3] Department of Anestesiology and Intensive Care Unit, Zealand University Hospital, Roskilde, Denmark. ^[4] Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. ^[5]